HomeAI · summaries
Storia in 6 fonti
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Merck & Co (NYSE:MRK), Gilead Sc
FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA backs Gilead’s Trodelvy for first-line, triple-negative breast cancer
FDA grants Gilead two first-line approvals for Trodelvy in triple-negative breast cancer, broadening its reach beyond Datroway's narrower indication.
- ·
fiercepharma.com
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway…
- ·
healio.com
Trodelvy earns FDA approval as first-line treatment for triple-negative breast cancer
The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or metastatic triple-negative breast cancer across PD-L1…
- ·
medpagetoday.com
TROP2 Drug Wins Two New Indications in Triple-Negative Breast Cancer
Sacituzumab govitecan approved alone or in combination for first-line treatment
- ·
benzinga.com
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Merck & Co (NYSE:MRK), Gilead Sc
FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.
- ·
morningstar.com
Tigerlily Foundation Celebrates FDA Approval of Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer
Tigerlily Foundation Celebrates FDA Approval of Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer